Compare AGM & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | OCS |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | Switzerland |
| Employees | 212 | 60 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | AGM | OCS |
|---|---|---|
| Price | $183.62 | $11.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $215.00 | $42.00 |
| AVG Volume (30 Days) | 118.8K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.97 | $466.06 |
| Revenue Next Year | $12.21 | $479.73 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $136.57 | $10.52 |
| 52 Week High | $210.64 | $34.48 |
| Indicator | AGM | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 27.22 |
| Support Level | $169.65 | $10.52 |
| Resistance Level | $185.70 | $21.82 |
| Average True Range (ATR) | 5.45 | 0.94 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 73.40 | 35.34 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.